Key facts
- This page summarizes Hans Moebius's Form 4 filing for Athira Pharma, Inc. (ATHA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 Jan 2024, 16:45.
Hans Moebius - 04 Jan 2024 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- ATHA
- Reported as of
- 04 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Jan 2024, 16:45:00 UTC
- Prior SEC filing
- 06 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Worthington, Attorney-in-Fact for Hans Moebius
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Hans Moebius filed Form 4 for Athira Pharma, Inc. (ATHA) on 08 Jan 2024.
Change
- Previous filing in this sequence was filed on 06 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATHA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +10,000
- Change %
- +12%
- Price
- $0.000000
- Shares after
- 91,482
- Date
- 04 Jan 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On November 3, 2021, the reporting person was granted restricted stock units ("RSUs") representing 30,000 shares of Common Stock of the Issuer. The RSUs are scheduled to vest according to the following amended vesting schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest as of the date the Compensation Committee (the "Committee") determines that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial has been completed, and (3) one third (1/3rd) of the number of shares subject to the RSU award vest as of the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the "LIFT-AD Readout"), in each case subject to continued service with the Issuer through the applicable vesting date.
Footnote F2
On January 4, 2023, the Committee determined that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial had been completed and 10,000 RSUs vested and settled on such date.